Lipid-lowering therapy
Breakthrough in Familial Chylomicronemia Syndrome: FDA Approves Ionis’ Tryngolza as First Treatment
Familial Chylomicronemia Syndrome (FCS), Ionis Tryngolza, FDA Approval, Rare Genetic Hyperlipidemia, Acute Pancreatitis, Lipid-Lowering Therapy
AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy
AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment